Bavarian Nordic A/S announced on 7 August 2013 that the European Commission has granted marketing authorization for Imvanex (MVA-BN) for...
The EU's CHMP has adopted a positive opinion recommending the granting of a marketing authorization for Imvanex vaccine, from Bavarian...
Bavarian Nordic A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the marketing authorization for the Company’s smallpox vaccine, Imvanex, is extended to include protecting people from monkeypox disease.
Bavarian Nordic A/S announced that the FDA has approved Jynneos (Smallpox and Monkeypox Vaccine, Live, Non-replicating) (MVA-BN, liquid-frozen) for prevention...